Health literacy and knowledge: varying understanding among health providers.
Background: Neurally adjusted ventilatory assist (NAVA) is a novel, neurally triggered, mode of ventilation. It uses the peak electrical activity of the diaphragm (Edi-peak) to trigger synchronised assist breaths, and to adjust inspiratory pressure to off-load respiratory work. It is also applicable for proportional noninvasive ventilation.
Methods: We evaluated the electrical activity of the diaphragm (Edi) changes during a crossover of respiratory support to or from non-invasive NAVA (NIV-NAVA) ventilation in premature infants. Edi data was downloaded following an elective decision made by the clinical team to either implement or wean off NAVA. Edi-peak, as well as Edi-min and infant respiratory rate were compared. Thirty-one 2-hour recordings from sick premature infants receiving NIV-NAVA ventilation were analysed to ascertain a reference range.
Results: Seven Edi recordings from 6 infants at the time of NAVA crossovers were evaluated. The mean Edi-peak during NAVA was significantly lower than that of CPAP or conventional ventilation modes. Mean Edi-min was significantly higher in NAVA, as was mean respiratory rate. The mean Edi-peak and Edi-min ascertained from 31 NIV-NAVA recordings from 8 infants was 7.54 (95% CI 6.72 -8.49) and 2.7 (95% CI 2.37 -3.06) respectively.
Conclusion: In this pilot study, NAVA synchronised ventilation results in a lower Edi-peak compared with other conventional modes of ventilation, and thus may correlate with a lower patient work of breathing. Further research is required to assess the true extent of the impact of this novel technology on the breathing patterns of premature infants. Background: In New South Wales in 2013 there was an outbreak of Human Parechovirus Type 3 (HPeV 3), which is now considered an emerging cause of disease in young infants. As this was the first cohort in NSW, parents are understandably concerned regarding the long-term outcomes for their infants. We aimed to describe the neurodevelopmental outcomes of a cohort of infants at both 12 months and 3 1/2 years hospitalised with HPeV infection in Sydney.
NEURODEVELOPMENTAL OUTCOMES FOLLOWING
Method: Outcomes at 12 months were assessed by telephone interview using standardised questionnaires including: Ages and Stages questionnaire version 3 ASQ3), Pediatric Quality of Life Inventory (PEDS-QoL) and the Liverpool Outcomes Score (LOS). At 3 ½ years infants were assessed using the Bayley Scales of Infant Development (BSID)-III and parental questionnaires, Results: Seventy nine children were admitted during the study period, and 46 of 79 were available for follow up at 12 months. Half (50%) had developmental concerns (ASQ3); 19% were rated as 'Significant', 31% rated as 'Some' concern with; most deficits in gross-motor and problem-solving domains. Infants with developmental concerns also had lower PEDS-QL and LOS scores. At 3 1/2 years, 50/79 Infants were assessed using the BSID-III, suggesting improvement and that most children scored in the normal range across all domains. . Conclusions: At 3 1/2 years post HPeV3 infection in infancy, the neurodevelopmental concerns observed at 12 months of age were less apparent. The three year results are reassuring, however, long term follow-up is required to better define the consequences of HPeV infection. Aim: To address the resource 'gap' by designing PTB_array (for spontaneous PTB in ethnically diverse groups), allowing genome-wide discovery, validation and fine-mapping regions of interest.
PRETERM BIRTH GENOME PROJECT (PGP) PHASE
Methods: Three classes of SNPs are included on the PTB_ar-ray.The first class include SNPs within fine-mapped regions of 1Mb interval of lead SNPs from i.Published GWAS with successful replication; ii.PGPII GWAS of spontaneous PTB in Caucasians; iii.Multi-ethnic meta-analysis of spontaneous PTB in five populations. The second class includes SNPs within dense genotyping of: i.Biologically plausible genes from recent publications; ii.Genes
